BioTelemetry has entered into a definitive agreement to acquire clinical trial imaging company VirtualScopics for approximately $15.5 million, the companies announced today.
“We are excited to further expand our clinical research offerings with the addition of VirtualScopics’ imaging capabilities,” Joseph H. Capper, BioTelemetry president and CEO, said in a prepared statement. “This acquisition demonstrates our continued commitment to growing our clinical research business. VirtualScopics possesses an excellent scientific and operational reputation and we look forward to building upon their longstanding relationships with their customers. We would like to welcome VirtualScopics’ employees and customers to the BioTelemetry family and we look forward to the successful completion of the merger.”
Eric Converse, VirtualScopics CEO, said the two companies are a good fit for one another.
“We believe BioTelemetry is the perfect partner for the future of VirtualScopics,” Converse said in the statement. “They possess the scale and resources to accelerate our growth plan and lead the company into the future. This is an exciting time for everyone at VirtualScopics and we look forward to joining the BioTelemetry team.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.